Loading...
•
Dec 31, 2022
HilleVax Q4 2022 Earnings Report
Reported full year financial results and highlighted recent company progress.
Key Takeaways
HilleVax reported its full year 2022 financial results, highlighting the initiation and execution of the Phase 2b clinical trial NEST-IN1 and the completion of its initial public offering.
Announced positive immunogenicity results for the NEST-IN1 run-in cohort in Q4 2022.
The company had cash and cash equivalents totaling $279.4 million as of December 31, 2022.
Research and development expenses for the fourth quarter 2022 were $17.6 million.
Net loss for the fourth quarter 2022 was $21.2 million.
HilleVax
HilleVax
Forward Guidance
HilleVax expects to complete enrollment of NEST-IN1 clinical trial in 2023 and announce top line safety and clinical efficacy data in the first quarter of 2024.